Supplementary Figure S3 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Federica Miglietta(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Angelo Paolo Dei Tos(University of Padua), Valerio Pellegrini(University of Padua), Andrea Vingiani(Istituti di Ricovero e Cura a Carattere Scientifico), Andrea Botticelli(Policlinico Umberto I), Valentina Guarneri(Istituto Oncologico Veneto), Francesca Porra(University of Padua), Matteo Fassan(University of Padua), Francesca Schiavi(Istituto Oncologico Veneto), Tommaso Giarratano(Istituto Oncologico Veneto), Marleen Kok(The Netherlands Cancer Institute), Giancarlo Pruneri(University of Milan), Lorenzo Nicolè(University of Padua), Gaia Griguolo(University of North Carolina at Chapel Hill), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Matilde Cacciatore(Ca' Foncello Hospital), Davide Massa(University of Padua), Manon de Graaf(Dutch Cancer Society), Giuseppe Fotia(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 0
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k